Edition:
India

People: Bio-Techne Corp (TECH.OQ)

TECH.OQ on NASDAQ Stock Exchange Global Select Market

212.45USD
15 Nov 2019
Change (% chg)

-- (--)
Prev Close
$212.45
Open
--
Day's High
--
Day's Low
--
Volume
--
Avg. Vol
62,778
52-wk High
$217.11
52-wk Low
$132.75

Eansor, David 

Mr. David Eansor is a Senior Vice President - Biotechnology of the Company. Prior to that, Mr. Eansor was Senior Vice President, Novus Biologicals, since the Company completed its acquisition of Novus on July 2, 2014. From January 2013 until the date of the acquisition, Mr. Eansor was the Senior Vice President of Corporate Development of Novus Biologicals. Prior to joining Novus, Mr. Eansor was the President of the Bioscience Division of Thermo Fisher Scientific. Mr. Eansor was promoted to Division President in early 2010 after 5 years as President of Thermo Fisher’s Life Science Research business.

Basic Compensation

Total Annual Compensation, USD 686,210
Restricted Stock Award, USD 162,522
Long-Term Incentive Plans, USD --
All Other, USD 498,473
Fiscal Year Total, USD 1,347,200

Options Compensation

  Quantity Market Value
Exercisable -- --
Unexercisable -- --
Exercised -- --
Name Fiscal Year Total

Robert Baumgartner

298,567

Charles Kummeth

9,076,890

James Hippel

2,226,770

Brenda Furlow

754,004

David Eansor

1,347,200

Robert Gavin

1,215,240
As Of  30 Jun 2017